• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Charles River Labs to lay off nearly 300 workers in Shrewsbury

Charles River Labs to lay off nearly 300 workers in Shrewsbury

January 11, 2010 By MassDevice staff

Charles River Laboratories International Inc. (NYSE:CRL) suspended operations at its preclinical services unit in Shrewsbury, a move that will result in about 300 layoffs.

About 30 of the 300 employees will be kept on to maintain the facility or be reassigned to other positions within the company, according to a spokeswoman for the Wilmington, Mass.-based contract research organization. Operations will resume at the facility when “global preclinical market conditions improve and the Company requires additional capacity,” according to a press release.

The preclinical unit provides the services required to take a drug through the development process, including discovery support, toxicology, pathology, as well as Phase I clinical trials, according to the company.

“This decision comes after a challenging year in which the consolidation of the biopharmaceutical industry, the slowdown in R&D efforts, and financial constraints for biotechnology companies resulted in softness in market demand for our services. As a result, we are suspending operations at our Shrewsbury facility,” CEO James Foster said in a prepared statement. Foster reiterated the company’s commitment to maintaining a presence in the Commonwealth.

The move isn’t a surprise, considering that CRL has been cutting jobs all year in its slumping preclinical unit as sales declined dramatically in 2009. The preclinical unit makes up about half of the company’s total revenue nut.

For the third quarter, sales fell 24 percent from the prior year, declining to $134.2 million. Overall, segment revenues are off 20 percent so far this year. The dropoff was less steep in Charles River’s research model segment, which saw a $2.4 million, or 1.4 percent, decline to $163.3 million.

Earlier this year, CRL began cutting jobs in its preclinical unit, as part of broader cost-cutting efforts, and laid off additional employees in October.

Company officials said the most recent round would result in a $7 million hit to the company’s bottom line in the first quarter, but is expected to result in a $20 million reduction in operating costs this year and about $25 million annually thereafter.

In the same statement, CRL reaffirmed its earnings guidance for 2009. The company said it expects overall sales to fall as much as 11 percent in 2009, with earnings in the range of $1.70 to $1.74 per share.

Filed Under: Business/Financial News, News Well, Research & Development Tagged With: Charles River Laboratories International Inc.

More recent news

  • Real-world data backs Route 92 reperfusion system
  • LivsMed unveils new surgical robot with telesurgery capabilities
  • JenaValve enrolls first patient in TAVR for AR study
  • HistoSonics expands insurance coverage for histotripsy treatment
  • Johnson & Johnson MedTech gets updated FDA nod for Varipulse PFA

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy